Sugi Predict

Sugi Predict / Compounds / SCHEMBL2290506

SCHEMBL2290506

SCHEMBL2290506

Cc1ccccc1[C@@H](C)OC(=O)Nc1c(C)noc1-c1ccc(-c2ccc(CC(=O)O)cc2)cc1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LPAR1 Q92633 16/20 0.83
▸ LPAR3 Q9UBY5 5/20 0.83
▸ LPAR2 Q9HBW0 2/20 0.83
▸ ABCC4 O15439 2/20 0.56
▸ ABCC3 O15438 1/20 0.56
▸ ABCB11 O95342 1/20 0.56
▸ CYP2C8 P10632 1/20 0.56
▸ CYP2C9 P11712 1/20 0.56
▸ ABCB4 P21439 1/20 0.56
▸ ABCC2 Q92887 1/20 0.56
▸ SLCO1B3 Q9NPD5 1/20 0.56
▸ SLCO1B1 Q9Y6L6 1/20 0.56
▸ KDM4E B2RXH2 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ LMNA P02545 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ PTGS1 P23219 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ FFAR1 O14842 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2294457 1.00 LPAR1 (0.83) LPAR1LPAR3LPAR2ABCC4ABCC3
SCHEMBL2297265 0.91 LPAR1 (0.80) LPAR1LPAR3LPAR2ABCC4ABCC3
SCHEMBL2292013 0.91 LPAR1 (1.00) LPAR1LPAR3LPAR2ABCC4ABCC3
SCHEMBL2294224 0.91 LPAR1 (1.00) LPAR1LPAR3LPAR2ABCC4ABCC3
SCHEMBL2294422 0.91 LPAR1 (0.80) LPAR1LPAR3LPAR2ABCC4ABCC3
SCHEMBL2294513 0.91 LPAR1 (0.80) LPAR1LPAR3LPAR2ABCC4ABCC3
SCHEMBL2289931 0.91 LPAR1 (0.80) LPAR1LPAR3LPAR2ABCC4ABCC3
SCHEMBL2287882 0.91 LPAR1 (1.00) LPAR1LPAR3LPAR2ABCC4ABCC3
SCHEMBL2289111 0.90 LPAR1 (0.68) LPAR1LPAR3LPAR2ABCC4ABCC3
SCHEMBL2289116 0.90 LPAR1 (0.68) LPAR1LPAR3LPAR2ABCC4ABCC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2358688-B1 ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS AMIRA PHARMACEUTICALS INC (US) 2014-03-12 — — EP claimed
US-8440707-B2 Antagonists of lysophosphatidic acid receptors AMIRA PHARMACEUTICALS, INC. (US) 2013-05-14 — — US claimed
US-20110301211-A1 ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS AMIRA PHARMACEUTICALS, INC. 2011-12-08 — — US claimed
US-20110301142-A1 ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS AMIRA PHARMACEUTICALS, INC. 2011-12-08 — — US claimed
US-8048902-B2 Antagonists of lysophosphatidic acid receptors AMIRA PHARMACEUTICALS, INC. (US) 2011-11-01 — — US claimed
US-20110196005-A1 ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS AMIRA PHARMACEUTICALS, INC., (US) 2011-08-11 — — US claimed
US-20100152257-A1 ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2010-06-17 — — US claimed
US-20150164874-A1 PIRFENIDONE AND ANTI-FIBROTIC THERAPY IN SELECTED PATIENTS INTERMUNE, INC. (US) 2015-06-18 — — US disclosed
EP-2358688-B1 ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS AMIRA PHARMACEUTICALS INC (US) 2014-03-12 — — EP disclosed
US-20130150426-A1 METHODS OF DIAGNOSING AND TREATING IDIOPATHIC PULMONARY FIBROSIS INTERMUNE, INC. (US) 2013-06-13 — — US disclosed
US-8440707-B2 Antagonists of lysophosphatidic acid receptors AMIRA PHARMACEUTICALS, INC. (US) 2013-05-14 — — US disclosed
US-8440707-B2 Antagonists of lysophosphatidic acid receptors AMIRA PHARMACEUTICALS, INC. (US) 2013-05-14 — — US disclosed
US-20110301142-A1 ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS AMIRA PHARMACEUTICALS, INC. 2011-12-08 — — US disclosed
US-8048902-B2 Antagonists of lysophosphatidic acid receptors AMIRA PHARMACEUTICALS, INC. (US) 2011-11-01 — — US disclosed
US-8048902-B2 Antagonists of lysophosphatidic acid receptors AMIRA PHARMACEUTICALS, INC. (US) 2011-11-01 — — US disclosed
US-20110196005-A1 ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS AMIRA PHARMACEUTICALS, INC., (US) 2011-08-11 — — US disclosed
US-20110196005-A1 ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS AMIRA PHARMACEUTICALS, INC., (US) 2011-08-11 — — US disclosed
WO-2010077882-A2 ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2010-07-08 — — WO disclosed
US-20100152257-A1 ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2010-06-17 — — US disclosed
US-20100152257-A1 ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2010-06-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152257-A1 ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS LPAR1, LPAR2, LPAR4 LPAR1 1/4885LPAR3 5/4885LPAR2 2/4885
US-20110196005-A1 ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS LPAR1, LPAR2, LPAR4 LPAR1 1/4885LPAR3 5/4885LPAR2 2/4885
US-20150164874-A1 PIRFENIDONE AND ANTI-FIBROTIC THERAPY IN SELECTED PATIENTS FIBP, PTGFR, MMP1 LPAR1 1534/4885LPAR3 747/4885LPAR2 1143/4885
US-20110301211-A1 ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS LPAR1, LPAR2, LPAR4 LPAR1 1/4885LPAR3 5/4885LPAR2 2/4885
US-20110301142-A1 ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS LPAR1, LPAR2, LPAR4 LPAR1 1/4885LPAR3 5/4885LPAR2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.